What is Wedbush’s Forecast for KNSA Q1 Earnings?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Equities research analysts at Wedbush increased their Q1 2025 earnings per share estimates for shares of Kiniksa Pharmaceuticals in a report released on Tuesday, February 25th. Wedbush analyst D. Nierengarten now anticipates that the company will earn $0.31 per share for the quarter, up from their prior estimate of $0.10. Wedbush has a “Outperform” rating and a $34.00 price target on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2025 earnings at $0.38 EPS, Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.69 EPS, FY2026 earnings at $2.55 EPS and FY2027 earnings at $3.24 EPS.

Separately, JPMorgan Chase & Co. raised their target price on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $36.60.

Kiniksa Pharmaceuticals Stock Performance

KNSA stock opened at $20.28 on Thursday. The business has a 50-day simple moving average of $19.66 and a two-hundred day simple moving average of $22.55. The company has a market capitalization of $1.46 billion, a P/E ratio of -144.85 and a beta of 0.32. Kiniksa Pharmaceuticals has a 52-week low of $16.56 and a 52-week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same period in the previous year, the company earned $0.35 earnings per share. Kiniksa Pharmaceuticals’s revenue for the quarter was up 46.9% compared to the same quarter last year.

Insider Buying and Selling

In other news, COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the completion of the sale, the chief operating officer now directly owns 81,975 shares of the company’s stock, valued at $1,604,250.75. This trade represents a 14.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares in the company, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,092 shares of company stock worth $745,589. 54.57% of the stock is owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its holdings in Kiniksa Pharmaceuticals by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock worth $195,000 after acquiring an additional 3,076 shares during the last quarter. AMI Asset Management Corp bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth $1,281,000. Rice Hall James & Associates LLC grew its position in shares of Kiniksa Pharmaceuticals by 8.2% in the third quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company’s stock valued at $16,234,000 after purchasing an additional 49,000 shares in the last quarter. Harbor Capital Advisors Inc. bought a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at $2,438,000. Finally, AlphaCentric Advisors LLC purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth about $287,000. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.